3026-iso, GBA N370S-correction/3026
CBIGi003-A-1
General
Cell Line |
|
hPSCreg name | CBIGi003-A-1 |
Cite as: | CBIGi003-A-1 (RRID:CVCL_C0K9) |
Alternative name(s) |
3026-iso, GBA N370S-correction/3026
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines |
EDi001-A-2 (AST23-1KO-3, AST22-1KO-3, AST-23_SCAKO Clone 3, AST-22_SNCAKO Clone 3) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease EDi001-A-3 (AST23_SNCAKO Clone 1, AST22-1KO-1, AST23-1KO-1, AST22_SNCAKO Clone 1) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease EDi001-A-4 (AST22-2KO-6, AST23_SNCAKO Clone 6, AST22_SNCAKO Clone 6, AST23-2KO-6) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease STBCi004-B-1 (SFC832-03-06 LRRK2WT/WT C47) Donor's gene variants: LRRK2 Donor diseases: Parkinson disease EDi001-A (AST22, AST23, SAMEA3319992) Donor's gene variants: SNCA, SNCA, SNCA Donor diseases: Parkinson disease |
Last update | 8th March 2022 |
Notes | Isogenic control for CBIGi003-A. |
User feedback | |
Provider |
|
Generator | Clinical Biospecimen Imaging and Genetic (C-BIG) Repository (CBIG) |
External Databases |
|
BioSamples | SAMEA13204589 |
Cellosaurus | CVCL_C0K9 |
Wikidata | Q112929373 |
General Information |
|
Publications | |
* Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Subclone of |
Donor Information
General Donor Information |
|
Sex | female |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
External Databases (Donor) |
|
BioSamples | SAMEA13204588 |
Ethics
Also have a look at the ethics information for the parental line
CBIGi003-A
.
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
The source cell information can be found in the parental cell line
CBIGi003-A.
|
|
Reprogramming method |
|
Vector type | Non-integrating |
Vector | Episomal |
Is reprogramming vector detectable? |
No |
Vector free reprogramming |
|
Other |
|
Derived under xeno-free conditions |
Unknown |
Derived under GMP? |
Unknown |
Available as clinical grade? |
Unknown |
Culture Conditions
Surface coating | Matrigel/Geltrex |
Feeder cells |
No |
Passage method |
Enzyme-free cell dissociation
Gentle Cell Dissociation Reagent
|
Medium |
mTeSR™ 1
|
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
NANOG |
Yes |
|
||||
POU5F1 (OCT-4) |
Yes |
|
||||
SSEA-4 |
Yes |
|
||||
TRA 1-60 |
Yes |
|
Differentiation Potency
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
46,XX
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
Genetic Modification
Genetic modifications not related to a disease |
|
Login to share your feedback, experiences or results with the research community.